Get the Stockscreener App
36.10
0.84%
0.30
After Hours:
36.10
Overview
News
Price History
Option Chain
Financials
Why BAX Down?
Discussions
Forecast
Stock Split
Dividend History
Baxter International Inc stock is traded at $36.10, with a volume of 2.56M.
It is up +0.84% in the last 24 hours and down -0.61% over the past month.
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. It has signed an agreement to sell its kidney care segment by early 2025.
See More
Previous Close:
$35.80
Open:
$35.7
24h Volume:
2.56M
Relative Volume:
0.72
Market Cap:
$18.26B
Revenue:
$15.00B
Net Income/Loss:
$2.48B
P/E Ratio:
7.0784
EPS:
5.1
Net Cash Flow:
$514.00M
1W Performance:
+0.31%
1M Performance:
-0.61%
6M Performance:
-2.14%
1Y Performance:
+6.30%
1-Day Range:
$35.30
$36.10
1-Week Range:
$35.30
$36.49
52-Week Range:
$32.48
$44.01
Baxter International Inc Stock (BAX) Company Profile
Name
Baxter International Inc
Sector
Industry
Phone
(847) 948-2000
Address
ONE BAXTER PKWY, DEERFIELD, IL
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-30-24 | Initiated | Goldman | Neutral |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-06-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-03-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-15-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jun-24-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-18-22 | Reiterated | KeyBanc Capital Markets | Overweight |
| Feb-18-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-18-22 | Reiterated | Raymond James | Outperform |
| Feb-18-22 | Reiterated | Stifel | Buy |
| Feb-18-22 | Reiterated | UBS | Neutral |
| Feb-18-22 | Reiterated | Wells Fargo | Overweight |
| Feb-11-22 | Initiated | Goldman | Neutral |
| Jan-07-22 | Resumed | Citigroup | Buy |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-21 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-03-21 | Upgrade | Barclays | Equal Weight → Overweight |
| May-25-21 | Initiated | Barclays | Equal Weight |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-06-21 | Downgrade | UBS | Buy → Neutral |
| Dec-15-20 | Downgrade | Goldman | Buy → Neutral |
| Oct-01-20 | Upgrade | Citigroup | Neutral → Buy |
| Sep-04-20 | Downgrade | Argus | Buy → Hold |
| Jun-24-20 | Initiated | Oppenheimer | Outperform |
| Mar-19-20 | Upgrade | Stifel | Hold → Buy |
| Mar-18-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-13-20 | Initiated | Goldman | Buy |
| Jan-02-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-17-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-26-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Apr-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-19 | Upgrade | Citigroup | Neutral → Buy |
| Jan-02-19 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Nov-02-18 | Upgrade | Argus | Hold → Buy |
| Oct-16-18 | Initiated | Barclays | Underweight |
| May-17-18 | Resumed | Piper Jaffray | Overweight |
| Feb-06-18 | Reiterated | Citigroup | Neutral |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-03-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
View All
Baxter International Inc Stock (BAX) Latest News
Impax Asset Management Group plc Cuts Stake in Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter - Supply Chain Digital
Hurricane Helene impact on Baxter to further limit IV fluid supply, HHS says - AOL
Baxter International Stock: Analyst Estimates & Ratings - Barchart
Baxter resumes limited production of IV solution products in Marion - Morganton News Herald
Baxter International (XSWX:BAX) Financial Strength : 4 (As of Jun. 2024) - GuruFocus.com
Baxter International (BSP:B1AX34) EBITDA per Share : R$8.04 (TTM As of Jun. 2024) - GuruFocus.com
Baxter International (BSP:B1AX34) Shares Outstanding (EOP) : 1,020 Mil (As of Jun. 2024) - GuruFocus.com
Baxter resumes limited production of IV solution products - Winston-Salem Journal
Baxter International Inc. (NYSE:BAX) Short Interest Update - MarketBeat
Baxter restarts major IV supplies line at hurricane-impacted plant - Medical Design & Outsourcing
Baxter International restarts IV fluid solutions manufacturing at largest plant - Fierce healthcare
Baxter International (BAX) Scheduled to Post Earnings on Friday - MarketBeat
Baxter Provides Update on Its North Carolina Manufacturing Plant - Healthcare Innovation
Baxter restarts some production of IV solutions at largest plant - Modern Healthcare
Baxter restarts IV solutions manufacturing line at hurricane-hit facility - Reuters
Baxter Says It Has Restarted Highest-Throughput IV Solutions Manufacturing Line - XM
Oneview Healthcare Expands Baxter Partnership and Reports Financial Growth - MSN
Exponential Growth Expected for Intravenous Solutions Market - openPR
Oneview Healthcare Expands with Baxter Partnership - TipRanks
UPDATED: Baxter exits China IV fluids market amid tough local competition, US shortage - FiercePharma
Baxter International Inc. (NYSE:BAX) Receives $41.20 Average Price Target from Analysts - MarketBeat
Oneview Healthcare and Baxter International Extend Value-Added Reseller Agreement for Two More Years and Expand the Agreement to include Canada - Tech Funding News
IV fluid maker says expiration date extensions approved - The Hill
Oneview and Baxter extend partnership to Canadian market - Yahoo Finance
Baxter International (WBO:BAX) PE Ratio : 7.37 (As of Oct. 29, 2024) - GuruFocus.com
Baxter could restart some IV lines by week’s end in McDowell County - Business North Carolina
Baxter International Inc. stock rises Monday, still underperforms market - MarketWatch
Baxter IV fluid facility in Marion closed by Helene flooding; bridges to property damaged - McDowell News
Employees returning to Helene damaged Baxter plant in Marion - Winston-Salem Journal
Oneview Healthcare Expands Partnership with Baxter - MSN
US Healthcare Giant Baxter Exits China's IV Therapy Market - Yicai Global
Oneview extends patient care platform agreement with Baxter in the US, and now, Canada - MSN
Baxter (BAX) to Cease IV Solution Operations in China Amid Marke - GuruFocus.com
Baxter Recalls Heparin Sodium Injection Over Elevated Endotoxin Levels - MSN
M&A News: Baxter Sells Kidney Care Unit to Carlyle for $3.8B - MSN
Baxter International Inc. stock underperforms Friday when compared to competitors - MarketWatch
Baxter International's Quarterly Earnings Preview: What You Need to Know - MSN
Baxter International's Quarterly Earnings Preview: What You Need To Know - Barchart
Baxter kidney care unit building R&D center for excellence in Golden Valley, creating 70 jobs - Star Tribune
Baxter expects to restart IV fluids line at hurricane-hit plant within next week - Reuters
Baxter to restart hurricane-damaged NC plant next week (NYSE:BAX) - Seeking Alpha
Troubles Mount for Baxter as Life2000 Slapped with Another Recall Notice - MD+DI
Baxter International IV plant shut down by Helene expected to restart production this week, CEO says - WCNC.com
Baxter Anticipates Restarting Highest-Throughput IV Solutions Manufacturing Line Within Next Week - XM
Coho Partners Ltd. Purchases New Stake in Baxter International Inc. (NYSE:BAX) - MarketBeat
National IV Fluid Shortage Could Affect Hospital Surgeries for Weeks - Inc.
Central Coast hospitals face IV fluid shortage after Baxter plant shutdown - KSBW Monterey
IV shortage update: Baxter facility damage after hurricane in North Carolina 2024 - American Medical Association
Baxter International (NYSE:BAX) Stock Rating Upgraded by StockNews.com - MarketBeat
Baxter International Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Baxter International Inc Stock (BAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.88%
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):